Home Companies Catalysts Deep Dives
Enlicitide MK-0616 PHASE3
Drug Profile
ModalityPeptide
RoutePO
Therapy AreaCVRM
Peak Sales Est$4000M
Formulations[]
Companies
MRK (ORIGINATOR)100%
Mechanism: Oral PCSK9 inhibitor
Expert: Oral small molecule PCSK9 inhibitor
Everyday: Lowers cholesterol with a pill instead of injection
Targets: ["PCSK9"]
Programs (1)
IndicationStageKey StudyRegional Status
HypercholesterolemiaPHASE3AMAZE[]
Notes
Oral PCSK9 inhibitor. Potential to disrupt injectable PCSK9 market. Phase 3 in hypercholesterolemia.
Data from Supabase · Updated 2026-03-24